Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Merck and Samsung BioLogics to Extend Strategic Alliance

Merck
Posted on: 01 Nov 17
Merck and Samsung BioLogics to Extend Strategic Alliance

PR Newswire

DARMSTADT, Germany, Nov. 1, 2017

- Alliance on biopharmaceutical manufacturing and biologics process development

- Merck would supply Mobius® single-use systems, cell line, cell culture media and chromatography to accelerate biologics development

DARMSTADT, Germany, Nov. 1, 2017 /PRNewswire/ -- Merck, a leading science and technology company, today announced the signing of a Memorandum of Understanding (MoU) with Samsung BioLogics for a strategic alliance on biopharmaceutical manufacturing and biologics process development.

The alliance would accelerate process development and clinical material production at small biotech start-ups focusing on novel drug development for which Samsung BioLogics acts as a contract manufacturer. Under the agreement, Merck would provide process development and support technical training, in addition to its Mobius® single-use systems to Samsung BioLogics.

The new MoU is an extension of a MoU signed in 2014 that encompasses a long-term supply agreement where Merck would provide raw materials for biopharmaceutical manufacturing.

"Our collaboration with Samsung continues to strengthen with this agreement," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "Merck's process development expertise and Mobius®, the wide single-use bioprocessing portfolio, will allow innovations to reach patients faster."

Merck has been the key solution provider for Samsung BioLogics' 30KL facility and 152KL facility in Korea, and has trained Samsung BioLogics team on building a robust biologics development process.

"This alliance will create synergy and maximize our technology potential," said Dr. Tae-Han Kim, President and CEO of Samsung BioLogics.

Merck's portfolio of Mobius® single-use systems delivers greater flexibility and continuity for scale-up, reducing the need to retrain operators. These are some of the multiple reasons that companies such as Samsung BioLogics have become early adopters of Merck's technologies.

At Merck's M Lab™ Collaboration Centers, customers work with the company's scientists and engineers in a shared exploratory environment to solve customers' toughest biomanufacturing challenges and help accelerate development of new therapies. Merck has nine M Lab™ Collaboration Centers around the world, including one in the U.S. and one in Korea.

Merck is a premier supplier of process development and clinical-stage manufacturing solutions, materials and services needed to produce biopharmaceutical drugs. The company is committed to delivering superior bioreactor technology to manufacturers, several of which are already collaborating with the company in that space in North America, Europe and Asia.

In the growing biopharmaceutical market, manufacturers are moving toward end-to-end solutions — from process development and scale-up through to manufacturing for pre-clinical, clinical and commercial supply — as they seek to cut costs while increasing quality and efficiency. At the same time, single-use, disposable equipment and systems have increased in popularity because they offer many advantages over conventional stainless steel systems, such as improved batch success rates, less cross-contamination risk, decreased water and waste water requirements, shortened project duration and reduced project costs.

About Samsung BioLogics
Samsung BioLogics is a global full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk cGMP manufacturing of drug substance and drug product including quality assurance, quality control, regulatory compliance standards & support for our customers. For additional information about the company, please visit www.samsungbiologics.com.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Photo - http://mma.prnewswire.com/media/592939/Merck_Samsung_handshake.jpg

PR Newswire
www.prnewswire.com

Last updated on: 01/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.